Table 1.
Effect of ABEC on serum cardiac biomarkers.
| Cardiac biomarkers | Group I (Control) |
Group II (Plant control) |
Group III (Dox Control) |
Group IV (ABEC + Dox) |
Group V (Positive control) |
|---|---|---|---|---|---|
| cTnI concentration (pg/mL) | 0.00 | 0.00 | 145.15 ± 10.77 | 21.85 ± 3.84*** | 11.46 ± 2.59*** |
| NT-pro BNP concentration (pg/mL) | 41.57 ± 7.29 | 35.86 ± 3.10 | 371.14 ± 9.69 | 198.57 ± 7.07*** | 159.43 ± 12.39*** |
| AST activity (U/L) | 25.71 ± 1.41 | 24.18 ± 1.60 | 66.10 ± 2.07 | 28.79 ± 1.98*** | 26.90 ± 1.26*** |
| LDH activity (U/L) | 1057.21 ± 38.6 | 1076.64 ± 49.8 | 1584.19 ± 83.4 | 1190.77 ± 77.2*** | 1104.97 ± 58.7*** |
ABEC; Aqueous bark extract of Cinnamomum zeylanicum, Dox; Doxorubicin, cTnI; cardiac Troponin I, NT-pro BNP; N-terminal pro brain natriuretic peptide, AST; Aspartate amino transferase, LDH; Lactate dehydrogenase. All values are expressed as mean ± SD (n = 10). p values: * < 0.05,**< 0.01, *** <0.001 compared to the doxorubicin control group (Group III).